Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price shot up 4.7% during mid-day trading on Thursday . The stock traded as high as $13.38 and last traded at $13.38. 36,795 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 227,627 shares. The stock had previously closed at $12.78.
Analyst Ratings Changes
Several brokerages have recently issued reports on MAZE. Guggenheim restated a "buy" rating and issued a $19.00 price objective on shares of Maze Therapeutics in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. began coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price objective for the company. Leerink Partnrs upgraded Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Leerink Partners started coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $28.00 price objective for the company. Finally, TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 25th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Maze Therapeutics has a consensus rating of "Buy" and a consensus price target of $25.67.
Get Our Latest Stock Report on Maze Therapeutics
Maze Therapeutics Stock Down 1.1%
The stock's 50-day moving average is $10.13.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Trading of Maze Therapeutics
Institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund acquired a new stake in Maze Therapeutics in the first quarter valued at approximately $25,000. Corebridge Financial Inc. acquired a new stake in shares of Maze Therapeutics in the first quarter worth approximately $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Maze Therapeutics in the first quarter worth approximately $57,000. Rhumbline Advisers acquired a new stake in shares of Maze Therapeutics in the first quarter worth approximately $80,000. Finally, Deutsche Bank AG acquired a new stake in shares of Maze Therapeutics in the first quarter worth approximately $98,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
